Inventor
AN ZHIQIANG
US42 patents
⚠️ This page may combine multiple inventors who share the name “AN ZHIQIANG”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
UNIV TEXAS
23 patentsUS9605057B1Mar 28, 2017
Endotrophin neutralization and use thereof
UNIV TEXAS5 citations81
US12202895B2Jan 21, 2025
LILRB4 antibodies and uses thereof
UNIV TEXAS2 citations73
US10875912B2Dec 29, 2020
EGFL6 specific monoclonal antibodies and methods of their use
UNIV TEXAS2 citations72
US10358501B2Jul 23, 2019
HER3 specific monoclonal antibodies for diagnostic and therapeutic use
UNIV TEXAS2 citations72
US9725520B2Aug 8, 2017
HER3 specific monoclonal antibodies for diagnostic and therapeutic use
UNIV TEXAS4 citations72
US11912758B2Feb 27, 2024
Methods of treating metastasis, including inhibiting bone cancer metastasis, by administering an antibody which binds connexin 43 (Cx43) hemichannel
UNIV TEXAS1 citations70
US10975142B2Apr 13, 2021
Endotrophin neutralization and use thereof
UNIV TEXAS1 citations70
US10889637B2Jan 12, 2021
Methods of treating an osteolytic tumor and spinal cord injury by administering connexin (Cx) 43 hemichannel-binding antibodies
UNIV TEXAS2 citations70
US10501538B2Dec 10, 2019
Anti-LILRB antibodies and their use in detecting and treating cancer
UNIV TEXAS5 citations70
US11629122B2Apr 18, 2023
Linkers for antibody drug conjugates
UNIV TEXAS4 citations65
US12152071B2Nov 26, 2024
EGFL6 specific monoclonal antibodies and methods of their use
UNIV TEXAS0 citations62
US11174320B2Nov 16, 2021
HER3 specific monoclonal antibodies for diagnostic and therapeutic use
UNIV TEXAS0 citations62
US12503500B2Dec 23, 2025
Connexin 43 (Cx43) hemichannel-binding antibodies
UNIV TEXAS0 citations60
US11906519B2Feb 20, 2024
Methods for identifying LILRB-blocking antibodies
UNIV TEXAS0 citations60
US11498963B2Nov 15, 2022
Anti-LILRB antibodies and their use in detecting and treating cancer
UNIV TEXAS0 citations60
US11377491B2Jul 5, 2022
Anti-leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) monoclonal antibodies and method of use thereof to treat cancer
UNIV TEXAS1 citations60
US12037390B2Jul 16, 2024
Leptin antibodies and method of reducing leptin
UNIV TEXAS0 citations59
US11760799B2Sep 19, 2023
Leptin antibodies
UNIV TEXAS0 citations59
US12331110B2Jun 17, 2025
Monoclonal antibodies against endotrophin and the use thereof
UNIV TEXAS0 citations57
US12570710B2Mar 10, 2026
Targeting LILRB4 with CAR-T or CAR-NK cells in the treatment of cancer
UNIV TEXAS0 citations56
US12084403B2Sep 10, 2024
Linkers for antibody drug conjugates
UNIV TEXAS0 citations53
US10221235B2Mar 5, 2019
Endotrophin neutralization and use thereof
UNIV TEXAS0 citations49
US12331130B2Jun 17, 2025
DDR1 antibodies and uses thereof
UNIV TEXAS0 citations47
MERCK & CO INC
3 patentsUS7754213B2Jul 13, 2010
High affinity antibody antagonists of interleukin-13 receptor alpha 1
MERCK & CO INC13 citations92
US7780963B2Aug 24, 2010
Anti-ADDL antibodies and uses thereof
MERCK & CO INC25 citations90
US7731962B2Jun 8, 2010
Anti-ADDL monoclonal antibody and use thereof
MERCK & CO INC8 citations83
MERCK SHARP & DOHME
3 patentsCSL LTD
3 patentsUS9777062B2Oct 3, 2017
High affinity antibody antagonists of interleukin-13 receptor alpha 1
CSL LTD1 citations62
US9371388B2Jun 21, 2016
High affinity antibody antagonists of interleukin-13 receptor alpha 1
CSL LTD2 citations62
US10106617B2Oct 23, 2018
High affinity antibody antagonists of interleukin-13 receptor alpha 1
CSL LTD0 citations51
NASH ANDREW DONALD
3 patentsUS8568722B2Oct 29, 2013
High affinity antibody antagonists of interleukin-13 receptor alpha 1
NASH ANDREW DONALD2 citations60
US8207304B2Jun 26, 2012
Antibody antagonists of interleukin-13 receptor α1
NASH ANDREW DONALD2 citations60
US8613925B2Dec 24, 2013
Anti-IL-13Rα1 antibodies and their uses thereof
NASH ANDREW DONALD1 citations50